Incannex Healthcare Achieves interim milestone in psilocybin trial
- Incannex Healthcare (IHL) achieves an interim milestone in its clinical trial to treat generalised anxiety disorder
- Twenty-nine patients of the 45 enrolled have now completed primary endpoint assessments as part of the company’s psilocybin-assisted psychotherapy study
- An interim analysis of the study data has now begun and is being carried out by an independent data safety monitoring board (DSMB)
- Incannex expects recommendations from the analysis to be provided in March 2023, with the trial set to continue
- IHL is trading 2.63 per cent higher at 19.5 cents at 11:30 am AEDT
